Top-Rated StocksTop-RatedNASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Forecast, Price & News $23.98 -0.07 (-0.29%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$23.30▼$24.7550-Day Range$18.95▼$25.3252-Week Range$12.08▼$33.49Volume154,265 shsAverage Volume289,920 shsMarket Capitalization$511.01 millionP/E RatioN/ADividend YieldN/APrice Target$53.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bicycle Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside122.2% Upside$53.20 Price TargetShort InterestBearish19.90% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 5 Articles This WeekInsider TradingSelling Shares$55,477 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.91) to ($5.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.58 out of 5 starsMedical Sector908th out of 1,006 stocksPharmaceutical Preparations Industry451st out of 492 stocks 3.5 Analyst's Opinion Consensus RatingBicycle Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.20, Bicycle Therapeutics has a forecasted upside of 122.2% from its current price of $23.94.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.90% of the outstanding shares of Bicycle Therapeutics have been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Bicycle Therapeutics has recently increased by 15.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCYC. Previous Next 1.3 News and Social Media Coverage News SentimentBicycle Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Bicycle Therapeutics this week, compared to 7 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,477.00 in company stock.Percentage Held by InsidersOnly 9.00% of the stock of Bicycle Therapeutics is held by insiders.Percentage Held by Institutions77.88% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($4.91) to ($5.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bicycle Therapeutics (NASDAQ:BCYC) StockBicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.Read More Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Stock News HeadlinesMay 31, 2023 | msn.comBrownsville’s Bicycle, Pedestrian and Child Safety CampaignMay 28, 2023 | es-us.finanzas.yahoo.comNYC Bicycle Accident Lawyer Glenn A. Herman Advocacy on Bicycle Accident Statistics in NYC in 2023May 31, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 27, 2023 | es-us.finanzas.yahoo.comBicycle Market Trends and ForecastThe global bicycle market is expected to reach an estimated $99.5 billion by 2028 with a CAGR of 5.9% 2022 to 2028May 25, 2023 | msn.comNew Bicycle Helmets Being Collected For Red Bank GiveawayMay 18, 2023 | seekingalpha.comBicycle Therapeutics (BCYC) Investor Presentation - SlideshowMay 17, 2023 | msn.comBicycle Therapeutics's Return On Capital Employed InsightsMay 14, 2023 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) OutlookMay 31, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 14, 2023 | seekingalpha.comBicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs YetMay 13, 2023 | americanbankingnews.comBicycle Therapeutics plc (NASDAQ:BCYC) Receives $53.20 Average Price Target from BrokeragesMay 12, 2023 | barrons.comBicycle Therapeutics and Orano Med Present Preclinical Bicycle(R) Radio-Conjugate Data at TIDES 2023May 11, 2023 | marketwatch.com8-K: BICYCLE THERAPEUTICS plcMay 11, 2023 | markets.businessinsider.com14 Analysts Have This to Say About Bicycle TherapeuticsMay 11, 2023 | finance.yahoo.comBicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023May 10, 2023 | bizjournals.comBayer inks $1.7B deal with Bicycle TherapeuticsMay 10, 2023 | markets.businessinsider.comBayer In Deal With Bicycle Therapeutics To Develop Radionuclide TherapiesMay 10, 2023 | reuters.comBayer, Bicycle Therapeutics in cancer radiotherapy drug allianceMay 10, 2023 | finance.yahoo.comBayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in OncologyMay 9, 2023 | msn.comOppenheimer Reiterates Bicycle Therapeutics Plc - ADR (BCYC) Outperform RecommendationMay 9, 2023 | americanbankingnews.comBicycle Therapeutics plc (NASDAQ:BCYC) Forecasted to Post FY2027 Earnings of $9.24 Per ShareMay 6, 2023 | msn.comHC Wainwright & Co. Reiterates Bicycle Therapeutics Plc - ADR (BCYC) Buy RecommendationMay 6, 2023 | nasdaq.comNeedham Maintains Bicycle Therapeutics Plc - ADR (BCYC) Buy RecommendationMay 5, 2023 | usnews.comFrance to Spend 2 Billion Euros to Boost Bicycle UsageMay 5, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Bicycle Therapeutics (BCYC)May 5, 2023 | msn.comPennDOT provides reminders for National Bicycle Safety MonthMay 4, 2023 | finance.yahoo.comWall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a BetSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Company Calendar Last Earnings11/03/2021Today5/31/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCYC CUSIPN/A CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees119Year FoundedN/APrice Target and Rating Average Stock Price Forecast$53.20 High Stock Price Forecast$74.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+121.7%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($4.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,720,000.00 Net Margins-801.45% Pretax Margin-812.57% Return on Equity-44.57% Return on Assets-29.19% Debt Debt-to-Equity Ratio0.13 Current Ratio7.19 Quick Ratio7.19 Sales & Book Value Annual Sales$14.46 million Price / Sales35.37 Cash FlowN/A Price / Cash FlowN/A Book Value$11.41 per share Price / Book2.10Miscellaneous Outstanding Shares21,310,000Free Float19,388,000Market Cap$511.44 million OptionableNot Optionable Beta0.75 Key ExecutivesKevin LeeChief Executive Officer & Executive DirectorLee H. KalowskiPresident & Chief Financial OfficerAlistair MilnesChief Operating OfficerMichael SkynnerChief Technology OfficerNicholas KeenChief Scientific OfficerKey CompetitorsCalliditas Therapeutics AB (publ)NASDAQ:CALTEvolusNASDAQ:EOLSPhathom PharmaceuticalsNASDAQ:PHATLiquidiaNASDAQ:LQDAEnanta PharmaceuticalsNASDAQ:ENTAView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 3,932 shares on 5/18/2023Ownership: 0.409%Armistice Capital LLCBought 736,000 shares on 5/16/2023Ownership: 3.455%First Light Asset Management LLCBought 2,896 shares on 5/16/2023Ownership: 3.282%Susquehanna International Group LLPBought 600 shares on 5/16/2023Ownership: 0.000%Jane Street Group LLCBought 9,800 shares on 5/16/2023Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions BCYC Stock - Frequently Asked Questions Should I buy or sell Bicycle Therapeutics stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCYC shares. View BCYC analyst ratings or view top-rated stocks. What is Bicycle Therapeutics' stock price forecast for 2023? 11 Wall Street research analysts have issued 12-month price targets for Bicycle Therapeutics' shares. Their BCYC share price forecasts range from $30.00 to $74.00. On average, they anticipate the company's stock price to reach $53.20 in the next year. This suggests a possible upside of 121.7% from the stock's current price. View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts. How have BCYC shares performed in 2023? Bicycle Therapeutics' stock was trading at $29.60 at the start of the year. Since then, BCYC stock has decreased by 18.9% and is now trading at $24.00. View the best growth stocks for 2023 here. When is Bicycle Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our BCYC earnings forecast. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics plc (NASDAQ:BCYC) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.02. The business earned $4.33 million during the quarter, compared to the consensus estimate of $5.29 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 44.57% and a negative net margin of 801.45%. What ETFs hold Bicycle Therapeutics' stock? ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Horizon Kinetics Medical ETF (MEDX), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Harbor Disruptive Innovation ETF (INNO), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC). When did Bicycle Therapeutics IPO? (BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Bicycle Therapeutics' stock symbol? Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC." Who are Bicycle Therapeutics' major shareholders? Bicycle Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Candriam S.C.A. (6.12%), Sio Capital Management LLC (4.54%), Logos Global Management LP (3.52%), Armistice Capital LLC (3.45%), First Light Asset Management LLC (3.28%) and AXA S.A. (2.16%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Michael Skynner, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bicycle Therapeutics' stock price today? One share of BCYC stock can currently be purchased for approximately $24.00. How much money does Bicycle Therapeutics make? Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $511.44 million and generates $14.46 million in revenue each year. The company earns $-112,720,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis. How many employees does Bicycle Therapeutics have? The company employs 119 workers across the globe. How can I contact Bicycle Therapeutics? Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503 or via email at david.borah@bicycletx.com. This page (NASDAQ:BCYC) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.